436 related articles for article (PubMed ID: 18412020)
1. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
3. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats.
Xie G; Wang X; Wang L; Wang L; Atkinson RD; Kanel GC; Gaarde WA; Deleve LD
Gastroenterology; 2012 Apr; 142(4):918-927.e6. PubMed ID: 22178212
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
[TBL] [Abstract][Full Text] [Related]
5. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
6. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
7. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
8. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
12. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090
[TBL] [Abstract][Full Text] [Related]
14. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats.
Jabs A; Oelze M; Mikhed Y; Stamm P; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Kopp M; Steven S; Schulz E; Stasch JP; Münzel T; Daiber A
Vascul Pharmacol; 2015 Aug; 71():181-91. PubMed ID: 25869522
[TBL] [Abstract][Full Text] [Related]
15. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.
Tsai EJ; Liu Y; Koitabashi N; Bedja D; Danner T; Jasmin JF; Lisanti MP; Friebe A; Takimoto E; Kass DA
Circ Res; 2012 Jan; 110(2):295-303. PubMed ID: 22095726
[TBL] [Abstract][Full Text] [Related]
16. The sGC activator BAY 60-2770 has potent erectile activity in the rat.
Lasker GF; Pankey EA; Frink TJ; Zeitzer JR; Walter KA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Jun; 304(12):H1670-9. PubMed ID: 23585129
[TBL] [Abstract][Full Text] [Related]
17. Different influences of extracellular and intracellular superoxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
J Cardiovasc Pharmacol; 2015 Feb; 65(2):160-7. PubMed ID: 25329747
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.
Schmidt P; Schramm M; Schröder H; Stasch JP
Eur J Pharmacol; 2003 May; 468(3):167-74. PubMed ID: 12754054
[TBL] [Abstract][Full Text] [Related]
20. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.
Nakane M; Kolasa T; Chang R; Miller LN; Moreland RB; Brioni JD
J Pharmacol Sci; 2006 Oct; 102(2):231-8. PubMed ID: 17050951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
